|
1
|
Fossati R, Confalonieri C, Torri V, et al:
Cytotoxic and hormonal treatment for metastatic breast cancer: a
systematic review of published randomized trials involving 31,510
women. J Clin Oncol. 16:3439–3460. 1998.PubMed/NCBI
|
|
2
|
Abal M, Andreu JM and Barasoain I:
Taxanes: microtubule and centrosome targets, and cell cycle
dependent mechanisms of action. Curr Cancer Drug Targets.
3:193–203. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Minotti G, Menna P, Salvatorelli E, Cairo
G and Gianni L: Anthracyclines: molecular advances and
pharmacologic developments in antitumor activity and
cardiotoxicity. Pharmacol Rev. 56:185–229. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schiff PB, Fant J and Horwitz SB:
Promotion of microtubule assembly in vitro by taxol. Nature.
277:665–667. 1979. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Frankel A, Buckman R and Kerbel RS:
Abrogation of taxol-induced G2-M arrest and apoptosis in human
ovarian cancer cells grown as multicellular tumor spheroids. Cancer
Res. 57:2388–2393. 1997.PubMed/NCBI
|
|
6
|
Sparano JA: Taxanes for breast cancer: an
evidence-based review of randomized phase II and phase III trials.
Clin Breast Cancer. 1:32–42. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cersosimo RJ and Hong WK: Epirubicin: a
review of the pharmacology, clinical activity, and adverse effects
of an adriamycin analogue. J Clin Oncol. 4:425–439. 1986.PubMed/NCBI
|
|
8
|
Knoop AS, Knudsen H, Balslev E, et al:
Retrospective analysis of topoisomerase IIa amplifications and
deletions as predictive markers in primary breast cancer patients
randomly assigned to cyclophosphamide, methotrexate, and
fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:
Danish Breast Cancer Cooperative Group. J Clin Oncol. 23:7483–7490.
2005.
|
|
9
|
Early Breast Cancer Trialists’
Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal
therapy for early breast cancer on recurrence and 15-year survival:
an overview of the randomised trials. Lancet. 365:1687–1717.
2005.PubMed/NCBI
|
|
10
|
Levine MN, Bramwell VH, Pritchard KI, et
al: Randomized trial of intensive cyclophosphamide, epirubicin, and
fluorouracil chemotherapy compared with cyclophosphamide,
methotrexate, and fluorouracil in premenopausal women with
node-positive breast cancer. National Cancer Institute of Canada
Clinical Trials Group. J Clin Oncol. 16:2651–2658. 1998.
|
|
11
|
Baselga J, Albanell J, Molina MA and
Arribas J: Mechanism of action of trastuzumab and scientific
update. Semin Oncol. 28:4–11. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sliwkowski MX, Lofgren JA, Lewis GD,
Hotaling TE, Fendly BM and Fox JA: Nonclinical studies addressing
the mechanism of action of trastuzumab (Herceptin). Semin Oncol.
26:60–70. 1999.PubMed/NCBI
|
|
13
|
Mirza AM, Gysin S, Malek N, Nakayama K,
Roberts JM and McMahon M: Cooperative regulation of the cell
division cycle by the protein kinases RAF and AKT. Mol Cell Biol.
24:10868–10881. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mullany LK, Nelsen CJ, Hanse EA, et al:
Akt-mediated liver growth promotes induction of cyclin E through a
novel translational mechanism and a p21-mediated cell cycle arrest.
J Biol Chem. 282:21244–21252. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yakes FM, Chinratanalab W, Ritter CA, King
W, Seelig S and Arteaga CL: Herceptin-induced inhibition of
phosphatidylinositol-3 kinase and Akt is required for
antibody-mediated effects on p27, cyclin D1, and antitumor action.
Cancer Res. 62:4132–4141. 2002.PubMed/NCBI
|
|
16
|
Montemurro F and Aglietta M: Incorporating
trastuzumab into the neoadjuvant treatment of HER2-overexpressing
breast cancer. Clin Breast Cancer. 6:77–80. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Montemurro F, Valabrega G and Aglietta M:
Trastuzumab-based combination therapy for breast cancer. Expert
Opin Pharmacother. 5:81–96. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Buzdar AU, Ibrahim NK, Francis D, et al:
Significantly higher pathologic complete remission rate after
neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin
chemotherapy: results of a randomized trial in human epidermal
growth factor receptor 2-positive operable breast cancer. J Clin
Oncol. 23:3676–3685. 2005. View Article : Google Scholar
|
|
19
|
Piccart-Gebhart MJ, Procter M,
Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in
HER2-positive breast cancer. N Engl J Med. 353:1659–1672. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Finkel T and Hwang PM: The Krebs cycle
meets the cell cycle: mitochondria and the G1-S transition. Proc
Natl Acad Sci USA. 106:11825–11826. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Detmer SA and Chan DC: Functions and
dysfunctions of mitochondrial dynamics. Nat Rev Mol Cell Biol.
8:870–879. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schieke SM, McCoy JP Jr and Finkel T:
Coordination of mitochondrial bioenergetics with G1 phase cell
cycle progression. Cell Cycle. 7:1782–1787. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mandal S, Guptan P, Owusu-Ansah E and
Banerjee U: Mitochondrial regulation of cell cycle progression
during development as revealed by the tenured mutation in
Drosophila. Dev Cell. 9:843–854. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jones RG, Plas DR, Kubek S, et al:
AMP-activated protein kinase induces a p53-dependent metabolic
checkpoint. Mol Cell. 18:283–293. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gwinn DM, Shackelford DB, Egan DF, et al:
AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol
Cell. 30:214–226. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Owusu-Ansah E, Yavari A, Mandal S and
Banerjee U: Distinct mitochondrial retrograde signals control the
G1-S cell cycle checkpoint. Nat Genet. 40:356–361. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tina E, Malakkaran Lindqvist B, Gabrielson
M, Lubovac Z, Wegman P and Wingren S: The mitochondrial transporter
SLC25A43 is frequently deleted and may influence cell proliferation
in HER2-positive breast tumors. BMC Cancer. 12:3502012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tina E, Prenkert M, Hoglund M, Paul C and
Tidefelt U: Topoisomerase IIα expression in acute myeloid leukaemia
cells that survive after exposure to daunorubicin or ara-C. Oncol
Rep. 22:1527–1531. 2009.
|
|
30
|
Lantz E, Cunningham I and Higa GM:
Targeting HER2 in breast cancer: overview of long-term experience.
Int J Womens Health. 1:155–171. 2010.PubMed/NCBI
|
|
31
|
Goldhirsch A, Ingle JN, Gelber RD, Coates
AS, Thurlimann B and Senn HJ: Thresholds for therapies: highlights
of the St Gallen International Expert Consensus on the primary
therapy of early breast cancer 2009. Ann Oncol. 20:1319–1329. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Butt AJ, Caldon CE, McNeil CM, Swarbrick
A, Musgrove EA and Sutherland RL: Cell cycle machinery: links with
genesis and treatment of breast cancer. Adv Exp Med Biol.
630:189–205. 2008.PubMed/NCBI
|
|
33
|
Gerdes J, Lemke H, Baisch H, Wacker HH,
Schwab U and Stein H: Cell cycle analysis of a cell
proliferation-associated human nuclear antigen defined by the
monoclonal antibody Ki-67. J Immunol. 133:1710–1715.
1984.PubMed/NCBI
|
|
34
|
Tudor G, Aguilera A, Halverson DO, Laing
ND and Sausville EA: Susceptibility to drug-induced apoptosis
correlates with differential modulation of Bad, Bcl-2 and Bcl-xL
protein levels. Cell Death Differ. 7:574–586. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sunters A, Madureira PA, Pomeranz KM, et
al: Paclitaxel-induced nuclear translocation of FOXO3a in breast
cancer cells is mediated by c-Jun NH2-terminal kinase and Akt.
Cancer Res. 66:212–220. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kutuk O and Letai A: Alteration of the
mitochondrial apoptotic pathway is key to acquired paclitaxel
resistance and can be reversed by ABT-737. Cancer Res.
68:7985–7994. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhou M, Zhao Y, Ding Y, et al: Warburg
effect in chemosensitivity: targeting lactate dehydrogenase-A
re-sensitizes taxol-resistant cancer cells to taxol. Mol Cancer.
9:332010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gogvadze V, Orrenius S and Zhivotovsky B:
Mitochondria as targets for chemotherapy. Apoptosis. 14:624–640.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tan M, Jing T, Lan KH, et al:
Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits
p34(Cdc2) activation and is involved in resistance to taxol-induced
apoptosis. Mol Cell. 9:993–1004. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lane HA, Motoyama AB, Beuvink I and Hynes
NE: Modulation of p27/Cdk2 complex formation through 4D5-mediated
inhibition of HER2 receptor signaling. Ann Oncol. 12(Suppl 1):
S21–S22. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nahta R, Takahashi T, Ueno NT, Hung MC and
Esteva FJ: P27(kip1) down-regulation is associated with trastuzumab
resistance in breast cancer cells. Cancer Res. 64:3981–3986. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chang J, Ormerod M, Powles TJ, Allred DC,
Ashley SE and Dowsett M: Apoptosis and proliferation as predictors
of chemotherapy response in patients with breast carcinoma. Cancer.
89:2145–2152. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
MacGrogan G, Mauriac L, Durand M, et al:
Primary chemotherapy in breast invasive carcinoma: predictive value
of the immunohistochemical detection of hormonal receptors, p53,
c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer. 74:1458–1465. 1996.
View Article : Google Scholar
|
|
44
|
Colleoni M, Viale G, Zahrieh D, et al:
Chemotherapy is more effective in patients with breast cancer not
expressing steroid hormone receptors: a study of preoperative
treatment. Clin Cancer Res. 10:6622–6628. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Rozan S, Vincent-Salomon A, Zafrani B, et
al: No significant predictive value of c-erbB-2 or p53 expression
regarding sensitivity to primary chemotherapy or radiotherapy in
breast cancer. Int J Cancer. 79:27–33. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Rau B, Sturm I, Lage H, et al: Dynamic
expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in
rectal carcinoma treated with preoperative radiochemotherapy. J
Clin Oncol. 21:3391–3401. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Pohl G, Rudas M, Taucher S, et al:
Expression of cell cycle regulatory proteins in breast carcinomas
before and after preoperative chemotherapy. Breast Cancer Res
Treat. 78:97–103. 2003. View Article : Google Scholar : PubMed/NCBI
|
